Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Oct 9, 2007

Rules-Based Medicine Acquires German Firm to Expand Biomarker Testing Services

  • Rules-Based Medicine (RBM) bought Experimentelle and Diagnostische Immunologie (EDI) thus combining their respective ex vivo biomarker testing platforms. EDI develops human organotypic (HOT) cell culture test systems, which RBM expects to have strong synergies with its multianalyte profiling (MAP) biomarker services.

    “Combining RBM’s MAP products and services with EDI’s HOT systems enables us to better serve both our existing and new customers,” notes T. Craig Benson, CEO of RBM. “These solutions will standardize sample collection, cell treatment, and result generation to provide investigators with the most reliable and reproducible approach to therapeutic and consumer product development.”

    EDI is based in Reutlingen, Germany, and will operate as a subsidiary of RBM. An EDI product, the instant leukocyte culture system (ILCS®), is designed to replace the peripheral blood mononuclear cell cultures. RBM says that it will couple ILCS with its MAP testing service to provide an understanding of a compound’s effects in the preclinical research phase.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »